Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06678552 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 2 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 3 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 4 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 5 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Cohort 6 | EXPERIMENTAL | Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics. |
| Name | Type | Description |
|---|---|---|
| PF-06678552 | DRUG | PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days. |
| Placebo | DRUG | PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days. |
Inclusion Criteria: * Healthy male and/or female subjects of non-childbearing potential. * Body Mass Index (BMI) of 18 to 30.5 kg/m2; and a total body weight \>50 kg * Low density lipoprotein cholesterol between 115 mg/dL and 190 mg/dL Exclusion Criteria: * Evidence or history of clinically signi...
PF-06678552 is an investigational small molecule being studied in healthy subjects. It is currently in Phase 1 clinical development, and the completed trial evaluated its safety and tolerability in healthy volunteers.
PF-06678552 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
PF-06678552 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
PF-06678552 has one completed Phase 1 trial, NCT02079922, titled 'A Multiple Dose Study Of PF-06678552 In Healthy Subjects.' This trial enrolled 38 healthy participants in Belgium and was randomized, double-blind, and controlled.
PF-06678552 is the primary name for this investigational small molecule. No alternative names have been reported for this drug in clinical development.